Synergy Pharmaceuticals
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Synergy Pharmaceuticals - overview
Location
New York, NY, US
Primary Industry
Biotechnology
About
Synergy Pharmaceuticals is focused on developing and marketing health supplements that enhance male sexual performance and overall wellness. Synergy Pharmaceuticals specializes in creating health supplements aimed at improving male sexual health. The company has its headquarters in New York, US. Gerrit Lawrence serves as CEO, and the company has engaged in one funding deal, the latest being on September 6, 2017.
Synergy Pharma specializes in developing and marketing a range of health supplements aimed at enhancing male sexual performance and overall well-being. Their primary product offerings include male enhancement supplements such as Semenax, ProSolution Plus, Male Extra, ExtenZe, VigRX Plus, Volume Pills, and Max Performer. These products address concerns like premature ejaculation, erectile dysfunction, and libido enhancement, targeting a diverse customer base across North America, Europe, and parts of Asia. Synergy Pharma operates on a direct-to-consumer sales model, where customers buy products through the company’s website.
Products like Semenax and VigRX Plus are sold at specific price points, encouraging bulk purchases that enhance customer loyalty and boost revenue. The company may also engage in promotional partnerships to increase sales volume across various retail platforms. Looking ahead, Synergy Pharmaceuticals aims to introduce new products focused on male sexual health supplements, with potential launches slated for late 2023. The company plans to expand its market reach into Latin America and Asia-Pacific by mid-2024.
The funds from the most recent deal will support these product development and geographic expansion initiatives.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.synergypharma.com
Total Amount Raised
Subscriber access only
Synergy Pharmaceuticals - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | Synergy Pharmaceuticals | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.